Both the Pharma and Dpharm will be the lead players. Others need to seek MOH regulatory approval. Best option { tie up with Pharma or Dpharm} for filling, process, procurement and distribution or logistics. Pharma and Dpharm have the network and logistics for distri ution. This vaccines need to move in special cold press isolation trucks { to ensure no contaminations or unnecessary risks}
When signing of MOU with China on vaccine takes place, the prices will spike. This should happen very soon as China is a great and efficient business partner.
US pharmaceutical giant Pfizer has begun manufacturing hundreds of thousands of doses of its COVID-19 vaccine ahead of its expected approval next month.
Worldwide infections spiral upwards with 40 million+ cases recorded yesterday. US, Brazil, India, EU {Spain, France, UK} hardest hit. WHO reaching out to China, UK, Russia, UK labs for a vaccine antidote. China has already started mass testing its vaccine
Yeah after remove these 4 % ikan bilis for profit taking, now we hold strong at this level, waiting mou news come out fly... Look at Mahsing just announce invest 12 line of gloves production already fly 100%,if China sign the deal, it won't be 100% only..
The big leap on their share prices, indeed, exceeded that of healthcare counters, namely Pharmaniaga Bhd that soared 420% during the period to RM5.50, as well as Duopharma Biotech Bhd which surged 261% to RM4.06 as at Oct 19.
The rise in both pharmaceutical counters were mainly driven by news that they would be taking part in the fill-and-finish process for a Covid-19 vaccine for Malaysia, besides the general optimism about the healthcare segment amid the pandemic.
Vaccine will become an urgency when no way to stop this virus
Covid-19 Vaccine: Pharmaniaga Says Its Plant Can Repackage 10 million Doses Per Month
Meanwhile, Mohamed Iqbal said Pharmaniaga is also on track to establish a halal vaccine facility — the world’s first — which is targeted for completion by 2022. “We have been planning this since 2018 and we are now looking at the implementation. This is not for Covid-19. This is for other vaccines such as to get your baby immunised when you travel. There are a few stages we will go through starting from trading, to fill and finish and eventually manufacturing our own kind. We will invest about RM100 million over the course of the next few years,” he said.
AstraZeneca shares turn negative after Brazilian health authority says volunteer in Covid vaccine study dies
(PUBLISHED WED, OCT 21 20201:15 PM EDTUPDATED 35 MIN AGO)
~ AstraZeneca shares turned negative after a Brazilian health authority, Anvisa, said a volunteer in its coronavirus vaccine study died.
~ The Federal University of Sao Paulo, which is helping coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters.
~ The news comes as the Food and Drug Administration still has a late-stage clinical trial from AstraZeneca on hold in the United States.
AstraZeneca shares turned negative Wednesday after a Brazilian health authority, Anvisa, said a volunteer in its coronavirus vaccine study died.
The Federal University of Sao Paulo, which is helping coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters.
Shares of AstraZeneca, a front-runner in the Covid-19 vaccine race, gave up a slight gain after the news broke. Shares were down by about 1% in early afternoon trading.
A spokesperson from AstraZeneca declined to comment on the volunteer, citing “medical confidentiality and clinical trial regulations.”
The spokesperson added that ”[a]ll significant medical events are carefully assessed by trial investigators” and ”[t]hese assessments have not led to any concerns about continuation of the ongoing study.”
In a statement, a spokesperson from the University of Oxford, which is developing the vaccine with AstraZeneca, said “there have been no concerns about safety of the clinical trial” after an assessment of the case in Brazil.
“The independent review in addition to the Brazilian regulator have recommended that the trial should continue,” Oxford spokesperson Alexander Buxton said.
Oxford provided no further details on the volunteer’s death, and it’s unclear if the volunteer received the vaccine. Brazil currently has the second deadliest outbreak in the world, behind the United States, with at least 115,914 deaths, according to data compiled by Johns Hopkins University.
A source familiar with the situation told Reuters that the trial would have been suspended if the volunteer had been a part of the group getting the shot.
The news comes as the Food and Drug Administration still has a late-stage clinical trial from AstraZeneca on hold in the United States. That means the company is unable to administer second doses of its two-dose vaccine regimen to U.S. participants.
The company announced on Sept. 8 that its trial had been put on hold due to an unexplained illness in a patient in the United Kingdom. The patient is believed to have developed inflammation of the spinal cord, known as transverse myelitis. The trial has since resumed in the U.K. and other countries.
The U.S. is expected to resume the trial as early as this week after the FDA completed its review, Reuters reported Tuesday, citing four anonymous sources.
AstraZeneca is one of four drugmakers backed by the U.S. in late-stage testing for a potential vaccine. AstraZeneca’s vaccine, called AZD1222, uses genetic material from the coronavirus with a modified adenovirus.
In July, the company published data that showed its vaccine produced a promising immune response in an early-stage trial and appeared to be well tolerated.
The vaccine produced no serious adverse events in volunteers, according to the researchers at the time. Fatigue and headache were the most commonly reported side effects, they said. Other common side effects included pain at the injection site, muscle ache, chills and a fever.
AstraZeneca's vaccine still not yet reach the safety consumption level...
Posted by Keyman188 > Oct 22, 2020 8:26 AM | Report Abuse X
AstraZeneca shares turn negative after Brazilian health authority says volunteer in Covid vaccine study dies
(PUBLISHED WED, OCT 21 20201:15 PM EDTUPDATED 35 MIN AGO)
~ AstraZeneca shares turned negative after a Brazilian health authority, Anvisa, said a volunteer in its coronavirus vaccine study died.
~ The Federal University of Sao Paulo, which is helping coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters.
~ The news comes as the Food and Drug Administration still has a late-stage clinical trial from AstraZeneca on hold in the United States.
The Brazilian newspaper O Globo, citing unnamed sources, reported that the volunteer was in a control group that did not receive the experimental vaccine and died of covid-19. The news service G1 said the volunteer was a 28-year-old physician who treated coronavirus patients in Rio de Janeiro.
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
MQ Trader 500 views | 2 d ago
0:17
New IPO: An enterprise IT solutions provider that provides implementation services, maintenance, support and professional services, Vetece Holdings Bhd aims to list on the Ace Market!
MQ Trader 586 views | 6 d ago
0:17
New IPO: A manufacturing and trading of biomass fuel products, particularly PKS and wood pellets company, Elridge Energy Holdings Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Plantermen
2,190 posts
Posted by Plantermen > 2020-10-19 07:30 | Report Abuse
Both the Pharma and Dpharm will be the lead players. Others need to seek MOH regulatory approval. Best option { tie up with Pharma or Dpharm} for filling, process, procurement and distribution or logistics. Pharma and Dpharm have the network and logistics for distri ution. This vaccines need to move in special cold press isolation trucks { to ensure no contaminations or unnecessary risks}